Michael H. Jones
University of Cambridge
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael H. Jones.
Proceedings of the National Academy of Sciences of the United States of America | 2002
Carl Virtanen; Yuichi Ishikawa; Daisuke Honjoh; Mami Kimura; Miyuki Shimane; Tatsu Miyoshi; Hitoshi Nomura; Michael H. Jones
The utility of cancer cell lines depends largely on their accurate classification, commonly based on histopathological diagnosis of the cancers from which they were derived. However, because cancer is often heterogeneous, the cell line, which also has the opportunity to alter in vitro, may not be representative. Yet without the overall architecture used in histopathological diagnosis of fresh samples, reclassification of cell lines has been difficult. Gene-expression profiling accurately reproduces histopathological classification and is readily applicable to cell lines. Here, we compare the gene-expression profiles of 41 cell lines with 44 tumors from lung cancer. These profiles were generated after hybridization of samples to four replicate 7,685-element cDNA microarrays. After removal of genes that were uniformly up- or down-regulated in fresh compared with cell-line samples, cluster analysis produced four major branch groups. Within these major branches, fresh tumor samples essentially clustered according to pathological type, and further subclusters were seen for both adenocarcinoma (AC) and small cell lung carcinoma (SCLC). Four of eight squamous cell carcinoma (SCC) cell lines clustered with fresh SCC, and 11 of 13 SCLC cell lines grouped with fresh SCLC. In contrast, although none of the 11 AC cell lines clustered with AC tumors, three clustered with SCC tumors and six with SCLC tumors. Although it is possible that preexisting SCC or SCLC cells are being selected from AC tumors after establishment of cell lines, we propose that, even in situ, AC will ultimately progress toward one of two poorly differentiated phenotypes with expression profiles resembling SCC or SCLC.
Human Genetics | 1994
Paul A. Crossey; Keith Foster; Frances M. Richards; Maude E. Phipps; Farida Latif; Kalman Tory; Michael H. Jones; Elizabeth Bentley; Ram Kumar; Michael I. Lerman; Bert Zbar; Nabeel A. Affara; Malcolm A. Ferguson-Smith; Eamonn R. Maher
Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome characterised by the development of retinal and central nervous system haemangioblastomas, renal cell carcinoma (RCC), phaeochromocytoma and pancreatic tumours. The VHL disease gene maps to chromosome 3p25-p26. To investigate the mechanism of tumourigenesis in VHL disease, we analysed 24 paired blood/tumour DNA samples from 20 VHL patients for allele loss on chromosome 3p and in the region of tumour suppressor genes on chromosomes 5, 11, 13, 17 and 22. Nine out of 24 tumours showed loss of heterozygosity (LOH) at at least one locus on chromosome 3p and in each case the LOH included the region to which the VHL gene has been mapped. Chromosome 3p allele loss was found in four tumour types (RCC, haemangioblastoma, phaeochromocytoma and pancreatic tumour) suggesting a common mechanism of tumourigenesis in all types of tumour in VHL disease. The smallest region of overlap was between D3S1038 and D3S18, a region that corresponds to the target region for the VHL gene from genetic linkage studies. The parental origin of the chromosome 3p25-p26 allele loss could be determined in seven tumours from seven familial cases; in each tumour, the allele lost had been inherited from the unaffected parent. Our results suggest that the VHL disease gene functions as a recessive tumour suppressor gene and that inactivation of both alleles of the VHL gene is the critical event in the pathogenesis of VHL neoplasms. Four VHL tumours showed LOH on other chromosomes (5q21, 13q, 17q) indicating that homozygous VHL gene mutations may be required but may not be sufficient for tumourigenesis in VHL disease.
British Journal of Cancer | 1994
K. Foster; Paul A. Crossey; P. Cairns; J. W. Hetherington; Frances M. Richards; Michael H. Jones; E. Bentley; Nabeel A. Affara; Malcolm A. Ferguson-Smith; Eamonn R. Maher
To investigate the role of tumour-suppressor genes on the short arm of chromosome 3 in the mechanism of tumorigenesis in non-familial renal cell carcinoma, we analysed 55 paired blood-tumour DNA samples for allele loss on chromosome 3p and in the region of known or putative tumour-suppressor genes on chromosomes 5, 11, 17 and 22. Sixty-four per cent (35/55) of informative tumours showed loss of heterozygosity (LOH) of at least one locus on the short arm of chromosome 3, compared with only 13% at the p53 tumour-suppressor gene and 6% at 17q21. LOH at chromosome 5q21 and 22q was uncommon (2-3%). Detailed analysis of the regions of LOH on chromosome 3p suggested that, in addition to the VHL gene in chromosome 3p25-p26, mutations in one or more tumour-suppressor genes in chromosome 3p13-p24 may be involved in the pathogenesis of sporadic renal cell carcinoma (RCC). We also confirmed previous suggestions that chromosome 3p allele loss is not a feature of papillary RCC (P < 0.05).
Human Molecular Genetics | 1998
Graeme M. Brown; Robert A. Furlong; Carole A. Sargent; Robert P. Erickson; Guy Longepied; Michael J. Mitchell; Michael H. Jones; Timothy B. Hargreave; Howard J. Cooke; Nabeel A. Affara
Genes, Chromosomes and Cancer | 1992
Michael H. Jones; Yusuke Nakamura
Human Molecular Genetics | 1996
Michael H. Jones; Robert A. Furlong; Heather R. Burkin; I.Jennifer Chalmers; Graeme M. Brown; Omar S. A. Khwaja; Nabeel A. Affara
Genomics | 2000
Michael H. Jones; Naeko Hamana; Jun-ichi Nezu; Miyuki Shimane
Genomics | 1997
Jun-ichi Nezu; Asuka Oku; Michael H. Jones; Miyuki Shimane
Genes, Chromosomes and Cancer | 1994
Michael H. Jones; Yusuke Nakamura; Sumiko Koi; Lkuno Fujimoto; Katsuhiko Hasumi; Kyoto Kato
Oncogene | 1992
Michael H. Jones; Yusuke Nakamura